Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.

Chen SY, Li JL, Meng FH, Wang XD, Liu T, Li J, Liu LS, Fu Q, Huang M, Wang CX.

Clin Transplant. 2013 May-Jun;27(3):E272-81. doi: 10.1111/ctr.12101. Epub 2013 Feb 24.

PMID:
23432535
2.

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.

Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.

Transplantation. 2012 Nov 27;94(10):1013-9. doi: 10.1097/TP.0b013e31826bc400.

PMID:
23073468
3.

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.

Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.

Clin Transplant. 2005 Oct;19(5):638-43.

PMID:
16146556
4.

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T.

Pharmacogenet Genomics. 2008 Apr;18(4):339-48. doi: 10.1097/FPC.0b013e3282f75f88.

PMID:
18334918
5.

Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.

Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P, Rousseau A.

Clin Pharmacokinet. 2012 Mar 1;51(3):175-86. doi: 10.2165/11594760-000000000-00000.

PMID:
22339449
6.

Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.

Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M.

Pharmacogenomics J. 2011 Aug;11(4):300-6. doi: 10.1038/tpj.2010.42. Epub 2010 Jun 1.

PMID:
20514078
7.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.

Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.

Pharmacogenet Genomics. 2013 May;23(5):251-61. doi: 10.1097/FPC.0b013e32835fcbb6.

PMID:
23459029
8.

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.

Transplantation. 2004 Oct 27;78(8):1182-7.

PMID:
15502717
9.

Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.

Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.

Pharmacogenet Genomics. 2014 Jul;24(7):356-66. doi: 10.1097/FPC.0000000000000060.

PMID:
24911663
10.

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.

Tang HL, Xie HG, Yao Y, Hu YF.

Pharmacogenet Genomics. 2011 Nov;21(11):713-20. doi: 10.1097/FPC.0b013e32834a48ca.

PMID:
21886016
11.

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.

Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.

12.
13.

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.

Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.

Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):546-52. doi: 10.1111/j.1742-7843.2008.00327.x.

14.

Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.

Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, Numakura K, Tsuchiya N, Tada H, Suzuki T, Habuchi T.

Br J Clin Pharmacol. 2008 Aug;66(2):207-14. doi: 10.1111/j.1365-2125.2008.03188.x. Epub 2008 Apr 22.

15.

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.

Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.

Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.

PMID:
17635182
16.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P.

Pharmacogenetics. 2004 Mar;14(3):147-54.

PMID:
15167702
17.
18.

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK.

Transplantation. 2003 Oct 27;76(8):1233-5.

PMID:
14578760
19.

Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.

Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V.

Ther Drug Monit. 2013 Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b.

PMID:
24052064
20.

Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.

Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE.

Ther Drug Monit. 2014 Feb;36(1):62-70. doi: 10.1097/FTD.0b013e31829f1ab8.

PMID:
24089074
Items per page

Supplemental Content

Write to the Help Desk